The prognostic value of endoglin (CD105) expression in ovarian carcinoma

Abstract

Intratumoral angiogenesis has become an important issue after the identification of antiangiogenic therapeutics. The purpose of this study was to investigate the prognostic value of CD105 in patients with ovarian cancer and also to compare with CD31. Fifty-eight patients were included to this study. All the paraffin blocks were reviewed, and angiogenesis was determined by immunohistochemical staining, using anti-CD105 and anti-CD31 monoclonal antibodies. The mean microvessel density (MVD) with CD105 and CD31 were 28.78 +/- 22.20 and 28.69 +/- 18.57, respectively (P = 0.97). With respect to prognostic factors, CD31 was only significant for suboptimal cytoreduction (P = 0.02), and CD105 was significant for both advanced stage and suboptimal cytoreduction (P = 0.02 and P = 0.05, respectively). For survival analysis, patients were divided into three groups by quartiles for each marker (group 1, <25%; group 2, 25-75%; and group 3, >75%). By CD31, only significant difference was noted between group 1 and group 2 (P = 0.03). In analysis with CD105, the survival rate of patients with group 3 was significantly worse than group 1 and group 2 (P = 0.01 for both). In multivariate analysis, cytoreduction and MVD determined by CD105 remained significant. In this study, endoglin was found to be an independent predictor of poor survival. Therefore, it could be used for antiangiogenic therapies.

Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy

“…Immunohistochemical analyses have shown increased endoglin expression in a variety of malignancies such as esophagus (35), lung (36), breast (37,38), ovary (39), endometrium (39), and prostate cancer (11). In addition, endoglin expression has been shown to be an independent predictor of outcome in endometrial and ovarian cancers (39,40). Plasma endoglin levels have been observed to be higher in patients who had metastases (10), suggesting elevated plasma endoglin levels could be a surrogate marker for tumor angiogenesis and, thereby, help identify early metastases during follow-up (9,10).…”

Stem Cell versus Cancer and Cancer Stem Cell: Intricate Balance Decides Their Respective Usefulness or Harmfulness in the Biological System

“…CSCs of various origins have been reported to express different marker proteins like ABCG2, ALDH1, CD44, CD24 and CD133, Thy-1, Sca-1 [45][46][47][48][49][50][51][52][53][54]. Such marker proteins, hence, have a great potential to be harnessed as biomarkers for CSCs.…”

Evaluation of Angiogenesis in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma: An Immunohistochemical Comparison Between Anti-Cd105 and Anti-Cd31 Antibodies.

“…However, CD105 was exclusively expressed on actively proliferating ECs of newly formed BVs but not on the normal pre-existing ones while CD31 was found to stain all BVs indiscriminately whether newly formed small or native large ones. Such finding is related to the selective staining of CD105 to actively proliferating ECs (Nagatsuka et al, 2005) on the contrary to CD31 which is not selective for epitopes on ECs but also aimed at those on inflammatory, mesechymal, neoplastic and non-neoplastic epithelial cells leading to their confused with microvessels (Taskiran et al, 2006). …”

“…However, the accuracy of MVD assessment with these pan-endothelial markers may not be the highest possible since they cannot distinguish newly formed tumoral blood vessels (BVs) from normal pre-existed BVs which in turn rises the need for a marker that is strictly specific for tumor-induced angiogenesis (Martone et al, 2005 andTaskiran et al, 2006). CD105 is a transforming growth factor beta (TGF-β) binding receptor preferentially expressed on endothelial cells (ECs) of all angiogenic tissues, including tumors, but weakly or not at all with those of normal tissues (Marioni et al, 2006) giving it the superiority as a marker with a greater specificity for tumor-induced angiogenesis.…”

“…A number of studies have shown the diagnostic and prognostic impact of CD105 in assisting tumor-induced angiogenesis in different solid malignancies such as skin cancer (Takahashi et al, 2001), breast carcinoma (Dales et al, 2003), prostatic cancer (Wikstrom et al, 2002), renal cell carcinoma (Costello et al, 2004), hepatocellular carcinoma (Ho et al, 2005) and ovarian carcinoma (Taskiran et al, 2006). CD31 is an integral membrane glycoprotein belongs to immunoglobulin (Ig) gene superfamily that is involved in tumor-induced angiogenesis by promoting EC proliferation, migration and adhesion (Paddock et al, 2011).…”